Raptor Pharmaceutical Corp. announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's Disease from Université Laval.Raptor's agreement with Laval provides exclusive rights to techno ... more
To use all functions of this page, please activate cookies in your browser.
